Provided by Tiger Fintech (Singapore) Pte. Ltd.

AN2 Therapeutics, Inc.

1.07
-0.0600-5.31%
Post-market: 1.110.0400+3.74%19:04 EDT
Volume:94.12K
Turnover:101.69K
Market Cap:32.29M
PE:-0.71
High:1.12
Open:1.12
Low:1.07
Close:1.13
Loading ...

Eric Easom, CEO of AN2 Therapeutics Inc., Reports Acquisition of Common Shares

Reuters
·
04 Jun

10% Owner Leonard Braden Michael Reports Disposal of AN2 Therapeutics Inc. Common Shares

Reuters
·
31 May

Director Margaret M. FitzPatrick reports acquisition of common shares of AN2 Therapeutics Inc

Reuters
·
30 May

AN2 Therapeutics to Present Poster on Epetraborole's Activity Against M. Abscessus at Colorado Mycobacteria Conference

Reuters
·
29 May

AN2 Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
28 May

BRIEF-AN2 Therapeutics Q1 Operating Expenses USD 11.537 Million

Reuters
·
14 May

AN2 Therapeutics Reports Q1 2025 Financials: Net Loss Narrows to $10.6 Million, R&D Expenses Decrease to $7.7 Million

Reuters
·
14 May

AN2 Therapeutics Q1 Operating Expenses USD 11.537 Million

THOMSON REUTERS
·
14 May

Bml Investment Partners-Sent Letter to AN2 Expressing Belief That Orderly Winddown, Liquidation, Capital Return Is in Best Interests of Shareholders

THOMSON REUTERS
·
07 May

Bml Investment Partners- Plans to Withhold Its Vote for All Three Directors at AN2's Upcoming Annual Meeting of Stockholders

THOMSON REUTERS
·
07 May

Bml Investment Partners Lp Reports 19.1% Stake in AN2 Therapeutics as of May 7 - SEC Filing

THOMSON REUTERS
·
07 May

AN2 Therapeutics Is Maintained at Market Outperform by JMP Securities

Dow Jones
·
05 May

AN2 Therapeutics Inc - Ebo-301 Phase 3 Study Misses Primary Endpoint in Mac Lung Disease

THOMSON REUTERS
·
02 May

AN2 Therapeutics Inc - Extends Cash Runway Into 2028

THOMSON REUTERS
·
02 May

AN2 Therapeutics Inc - Topline Data for Melioidosis Trial Expected in 2Q25

THOMSON REUTERS
·
02 May

AN2 Therapeutics Reports Data From the Phase 3 Portion of Previously Terminated Ebo-301 Study and Outlines Future Milestones From Boron Chemistry Pipeline

THOMSON REUTERS
·
02 May

AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline

Business Wire
·
02 May

AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference

Business Wire
·
30 Apr

AN2 Therapeutics, Inc. (ANTX) Receives a Sell from Evercore ISI

TIPRANKS
·
01 Apr

AN2 Therapeutics, Inc.: Promising Future with Strong Financial Health and Strategic Advancements

TIPRANKS
·
26 Mar